Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:DSGN NASDAQ:IMUX NASDAQ:JBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$3.16-4.7%$2.79$0.87▼$6.14$320.33M0.99919,292 shs1.01 million shsDSGNDesign Therapeutics$5.61-3.8%$6.00$2.60▼$7.77$319.49M1.68147,535 shs49,524 shsIMUXImmunic$0.83-0.6%$0.87$0.56▼$1.73$81.88M1.561.29 million shs1.10 million shsJBIOJade Biosciences$10.47+4.7%$8.12$6.57▼$105.00$341.61M1.05155,329 shs214,795 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+8.88%+8.88%+9.24%+92.44%-33.67%DSGNDesign Therapeutics+1.57%-10.17%-3.64%+37.18%+4.20%IMUXImmunic+4.51%-6.51%-1.02%-10.65%-47.40%JBIOJade Biosciences+6.72%+10.01%+34.77%+11.36%+999,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$3.16-4.7%$2.79$0.87▼$6.14$320.33M0.99919,292 shs1.01 million shsDSGNDesign Therapeutics$5.61-3.8%$6.00$2.60▼$7.77$319.49M1.68147,535 shs49,524 shsIMUXImmunic$0.83-0.6%$0.87$0.56▼$1.73$81.88M1.561.29 million shs1.10 million shsJBIOJade Biosciences$10.47+4.7%$8.12$6.57▼$105.00$341.61M1.05155,329 shs214,795 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+8.88%+8.88%+9.24%+92.44%-33.67%DSGNDesign Therapeutics+1.57%-10.17%-3.64%+37.18%+4.20%IMUXImmunic+4.51%-6.51%-1.02%-10.65%-47.40%JBIOJade Biosciences+6.72%+10.01%+34.77%+11.36%+999,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$4.1732.02% UpsideDSGNDesign Therapeutics 1.00SellN/AN/AIMUXImmunic 2.86Moderate Buy$9.501,043.20% UpsideJBIOJade Biosciences 2.60Moderate Buy$19.0081.47% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, ALEC, DSGN, and JBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025IMUXImmunicLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/9/2025JBIOJade BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.0010/9/2025JBIOJade BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.0010/8/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMUXImmunicWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025JBIOJade BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E-)9/29/2025IMUXImmunicChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.009/27/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMUXImmunicWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M3.18N/AN/A$1.29 per share2.45DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AIMUXImmunicN/AN/AN/AN/A$0.20 per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)IMUXImmunic-$100.51M-$0.94N/AN/AN/AN/A-461.46%-217.16%11/6/2025 (Estimated)JBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/ALatest IMUX, ALEC, DSGN, and JBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025DSGNDesign Therapeutics-$0.34N/AN/AN/AN/AN/A11/6/2025Q3 2025IMUXImmunic-$0.18N/AN/AN/AN/AN/A11/5/2025Q3 2025ALECAlector-$0.40N/AN/AN/A$3.49 millionN/A8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A8/7/2025Q2 2025IMUXImmunic-$0.18-$0.20-$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78DSGNDesign TherapeuticsN/A25.1325.13IMUXImmunicN/A2.192.19JBIOJade BiosciencesN/A10.3110.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%DSGNDesign Therapeutics56.64%IMUXImmunic51.82%JBIOJade BiosciencesN/AInsider OwnershipCompanyInsider OwnershipALECAlector9.70%DSGNDesign Therapeutics23.50%IMUXImmunic4.60%JBIOJade Biosciences24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableIMUXImmunic7098.65 million94.11 millionOptionableJBIOJade Biosciences2032.63 million24.50 millionN/AIMUX, ALEC, DSGN, and JBIO HeadlinesRecent News About These CompaniesJade Biosciences to Present Preclinical Safety and Clinical Development Insights for JADE101 in IgA Nephropathy at ASN Kidney Week 2025October 17, 2025 | quiverquant.comQJade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025October 17, 2025 | globenewswire.comWedbush Equities Analysts Lower Earnings Estimates for JBIOOctober 12, 2025 | americanbankingnews.comQ3 Earnings Forecast for Jade Biosciences Issued By WedbushOctober 11, 2025 | marketbeat.comJade Biosciences (NASDAQ:JBIO) Upgraded to Strong-Buy at BTIG ResearchOctober 11, 2025 | marketbeat.comBTIG Initiates Coverage of Jade Biosciences (JBIO) with Buy RecommendationOctober 10, 2025 | msn.comJade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comJade Biosciences initiated with a Buy at BTIGOctober 9, 2025 | msn.comJade Biosciences (NASDAQ:JBIO) Receives Sell (E-) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comJade Biosciences up 16.5% at $10.65 after JADE201 announcementOctober 7, 2025 | msn.comJade Biosciences prices 13.4M shares at $9.14 in private placementOctober 7, 2025 | msn.comJade Biosciences Shares Jump 20% After Revealing Promising Autoimmune Therapy and $135 Million Funding RoundOctober 7, 2025 | msn.comJade Biosciences Launches JADE201, an Advanced Anti-BAFF-R Monoclonal Antibody for Autoimmune Diseases with Enhanced Durability and Dosing ConvenienceOctober 7, 2025 | quiverquant.comQJade Biosciences, Inc. Secures $135 Million in PIPE Financing to Support Development of Autoimmune Disease TherapiesOctober 7, 2025 | quiverquant.comQJade Biosciences Secures $135 Million in Private PlacementOctober 7, 2025 | tipranks.comJade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune DiseasesOctober 7, 2025 | globenewswire.comJade Biosciences Announces $135 Million Private PlacementOctober 7, 2025 | globenewswire.comJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of ...September 2, 2025 | bakersfield.comBJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being ...September 2, 2025 | finance.yahoo.comJade Biosciences Initiates Phase 1 Trial for JADE101 as Potential Disease-Modifying Treatment for IgANSeptember 2, 2025 | quiverquant.comQJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathySeptember 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, ALEC, DSGN, and JBIO Company DescriptionsAlector NASDAQ:ALEC$3.16 -0.16 (-4.68%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Design Therapeutics NASDAQ:DSGN$5.61 -0.22 (-3.77%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Immunic NASDAQ:IMUX$0.83 -0.01 (-0.65%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Jade Biosciences NASDAQ:JBIO$10.47 +0.47 (+4.70%) As of 02:29 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
